Try our Advanced Search for more refined results
Life Sciences
-
February 18, 2026
Levi & Korsinsky To Lead Novo Nordisk Investor Class Action
Levi & Korsinsky LLP has been appointed lead counsel in a proposed securities class action accusing Novo Nordisk A/S of misleading investors about its 2025 revenue outlook, after a New Jersey federal judge approved the firm's selection by the investor with the largest financial stake in the case.
-
February 18, 2026
Paul Hastings Adds Cooley Atty As Life Science Deals Leader
Paul Hastings LLP announced Wednesday that it has tapped a former Cooley LLP partner and onetime Merck & Co. attorney to chair its life sciences transactions team.
-
February 17, 2026
Judge Trims Moderna's Defenses In COVID Patent Suit
A federal judge sitting in Delaware on Tuesday ruled that Moderna could not use obviousness to defend itself from patent claims brought by a rival vaccine developer since it already used that as a defense in related Patent Trial and Review Board proceedings, saying that Moderna had offered expert opinions to support a defense that the patents don't sufficiently teach about the claimed invention.
-
February 17, 2026
Judge Rips Drugmakers' Borderline 'Disingenuous' Appeal Bid
A Connecticut federal judge has rejected generic-drug makers' request for a quick appeal of his ruling denying them summary judgment on states' claims they engaged in an "overarching conspiracy" to fix prices, slamming the request for being borderline "disingenuous," mischaracterizing his reasoning and ignoring direct evidence of alleged wrongdoing.
-
February 17, 2026
Union Says Express Scripts Diverted Billions In Kickback Fees
A Chicago plumbers union healthcare fund told an Illinois federal court Tuesday that the nation's largest pharmacy benefit manager, Express Scripts, violated federal criminal law when it used a Switzerland-based company to hide kickbacks it generated by charging drug companies fees for key placement on prescription plan drug lists.
-
February 17, 2026
Squires Ends IPR After ITC Judge Rejects Validity Challenge
U.S. Patent and Trademark Office Director John Squires ended a Patent Trial and Appeal Board review of a Hydrafacial LLC skin treatment patent since the same issue had already been adjudicated in the U.S. International Trade Commission.
-
February 17, 2026
Cohen Milstein To Rep Perrigo Investors In Formula Biz Suit
Cohen Milstein Sellers & Toll PLLC will represent a proposed class of Perrigo Company PLC investors who allege the company failed to disclose critical issues with infant formula operations that it purchased from Nestlé and caused stock prices to drop as the issues came to light.
-
February 17, 2026
McGuireWoods Adds Sidley Private Equity Pro In Los Angeles
McGuireWoods LLP is expanding its transactional team, announcing Tuesday that it is bringing in a Sidley Austin LLP private equity expert as a partner in its Los Angeles office.
-
February 17, 2026
J&J Fights Beasley Allen's Bid To Pause Talc DQ Ruling
A New Jersey state court lacks standing to block an appellate panel's removal of Beasley Allen from representing hundreds of women with ovarian cancer pursuing claims against Johnson & Johnson over talcum powder, the pharmaceutical company has argued in an opposition brief.
-
February 17, 2026
Edwards Sued In Chancery Over $300M Heart Valve Earn-Out
The former shareholders of Valtech Cardio Ltd. have sued the company and its parent Edwards Lifesciences Corp. in the Delaware Chancery Court, accusing the medical device giant of deliberately stalling development of a heart valve repair system to avoid paying up to $300 million in earn-out consideration tied to the 2016 acquisition.
-
February 17, 2026
Philips Settles Suit Over Sleep Machine Starting Home Fire
Medical equipment company Philips has reached a deal with a woman who alleged in North Carolina federal court that its sleep apnea breathing machine caught fire and caused burns to her mother's face and destroyed her home.
-
February 13, 2026
RFK Jr. Taps Ex-Jones Day Atty For FDA Senior Counselor
U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. has named a former Jones Day partner as one of the U.S. Food and Drug Administration's senior counselors, according to an announcement.
-
February 13, 2026
States' Generic Drugs Antitrust Case Headed Toward Trial
A Connecticut federal judge has mostly refused to side with pharmaceutical companies facing states' generic drug price-fixing litigation against them, ruling that there are genuine disputes of material fact as to drug distribution chains and the states' antitrust standing and teeing up the case for trial.
-
February 13, 2026
Chewy Settles Antitrust Claims Over Elanco Flea & Tick Meds
Chewy has reached a settlement with consumers in a case accusing Elanco Animal Health Inc. of paying several pet supply retailers not to stock generic versions of its Advantix topical flea and tick prevention drugs.
-
February 13, 2026
Docs Urge Judge To Block CDC's Childhood Vaccine Changes
Doctors organizations Friday urged a Massachusetts federal judge to stop the government from implementing its new, shorter list of recommended vaccines for children and prevent the next meeting of a committee they say has been tainted by anti-vaccine influence.
-
February 13, 2026
Reed Smith Nabs Ex-WilmerHale Capital Markets Pro
Reed Smith LLP has hired a former WilmerHale attorney who specializes in corporate and securities matters as a global corporate group partner in Denver for the firm's business and finance department.
-
February 13, 2026
Iowa AG Urges 8th Circ. To Unblock Parts Of State PBM Law
The state of Iowa urged the Eighth Circuit on Friday to lift a preliminary block on parts of a law limiting pharmacy benefit managers' power to set drug prices in the Hawkeye State, arguing a lower court judge erred in holding that parts of the policy were federally preempted.
-
February 13, 2026
FDA Removes Boxed Warnings From HRT Products
Six menopause hormone therapies will no longer have warnings on their label about heart disease, breast cancer and dementia, after the U.S. Food and Drug Administration said it removed them so that women can make decisions "free from exaggeration or fear."
-
February 13, 2026
How Attorneys Are Handling A Patent Review 'Sea Change'
Major changes to the America Invents Act patent review system over the past year have put limits on challenges, requiring patent challengers and owners to rethink their strategies. Here's how attorneys on both sides are calibrating their arguments to have the best chance of success in the new landscape.
-
February 13, 2026
J&J Hit With $250K Verdict In 2nd Philly Talc Trial
A Philadelphia jury hit Johnson & Johnson with a $250,000 verdict on Friday, finding the company liable in the case of a woman whose family claimed that using the company's once-famous talcum powder contributed to her fatal ovarian cancer.
-
February 13, 2026
CareDx Seeks High Court Review Of $45M False Ad Case
Transplant diagnostics company CareDx has asked the U.S. Supreme Court to review a Third Circuit decision that erased a nearly $45 million jury award against rival Natera in a false advertising case, arguing the appeals court is the only one that forbids juries from inferring consumer deception when determining damages.
-
February 13, 2026
Prenatal Testing Co. Missed Fatal Condition, Couple Say
A Massachusetts couple say Natera Inc. misreported the results of tests for a genetic marker linked to a fatal kidney condition, leading to the conception of a child who died an hour after birth.
-
February 12, 2026
FTC's PBM Case Paused For More Deal Talks
Federal Trade Commission staffers are discussing potential settlements with OptumRx and Caremark that could end the agency's case accusing the pharmacy benefit managers of inflating insulin prices, following a recent deal with Express Scripts.
-
February 12, 2026
Ex-Pharma Exec Fights AGs' Quick Win Bid In Antitrust Case
A former pharmaceutical marketing executive urged a Connecticut federal court to reject summary judgment sought against him by state attorneys general pursuing wider price-fixing litigation against most of the generic drug industry, arguing key cooperating witnesses' questionable credibility makes a trial necessary.
-
February 12, 2026
Astellas Gets $120M From Zydus In Bladder Drug Deal
Generic-drug maker Zydus Pharmaceuticals has inked a $120 million deal to end a lawsuit accusing it of infringing Astellas Pharma Inc. patents covering bladder drug Myrbetriq, just two days after Lupin Pharmaceuticals made a similar deal.
Expert Analysis
-
Series
Writing Musicals Makes Me A Better Lawyer
My experiences with writing musicals and practicing law have shown that the building blocks for both endeavors are one and the same, because drama is necessary for the law to exist, says Addison O’Donnell at LOIS Law.
-
Between The Lines Of EPO's Adoption Of Color Drawings
The European Patent Office's decision to accept patent drawings in color starting in October may enhance clarity in technical disclosures and streamline the examination process, and could also enable new patent filing strategies for international applicants, say attorneys at Miller Canfield.
-
What Prop 65 Ruling Means For Cosmetics, Personal Care Biz
A California federal court's recent decision on Proposition 65 warnings is good news for companies in the cosmetics and personal care space, as it will relieve businesses of the need to apply such warnings to products containing titanium dioxide and likely stop a wave of pending failure-to-warn litigation, say attorneys at Morgan Lewis.
-
Series
Adapting To Private Practice: From Va. AUSA To Mid-Law
Returning to the firm where I began my career after seven years as an assistant U.S. attorney in Virginia has been complex, nuanced and rewarding, and I’ve learned that the pursuit of justice remains the constant, even as the mindset and client change, says Kristin Johnson at Woods Rogers.
-
2 Fed. Circ. Rulings Underscore Patent Prosecution Pitfalls
Two recent patent decisions from the Federal Circuit, overturning significant judgments, serve as reminders that claim modifications and cancellations may have substantive effects on the scope of other claims, and that arguments distinguishing prior art and characterizing claims may also limit claim scope, say attorneys at Morgan Lewis.
-
Rebutting Price Impact In Securities Class Actions
Defendants litigating securities cases historically faced long odds in defeating class certification, but that paradigm has recently begun to shift, with recent cases ushering in a more searching analysis of price impact and changing the evidence courts can consider at the class certification stage, say attorneys at Katten.
-
7 Document Review Concepts New Attorneys Need To Know
For new associates joining firms this fall, stepping into the world of e-discovery can feel like learning a new language, but understanding a handful of fundamentals — from coding layouts to metadata — can help attorneys become fluent in document review, says Ann Motl at Bowman and Brooke.
-
Ruling On Labor Peace Law Marks Shift For Cannabis Cos.
Currently on appeal to the Ninth Circuit, an Oregon federal court’s novel decision in Casala v. Kotek, invalidating a state law that requires labor peace agreements as a condition of cannabis business licensure, marks the potential for compliance uncertainty for all cannabis employers in states with labor peace mandates, say attorneys at Sheppard Mullin.
-
Fed. Circ. Rulings Refine Patent Claim Construction Standards
Four Federal Circuit patent decisions this year clarify several crucial principles governing patent claim construction, including the importance of prosecution history, and the need for error-free, precise language from claims drafters, say attorneys at Taft.
-
How Value-Based Patent Fees May Shape IP Strategies
If the U.S. Patent and Trademark Office implements rumored plans to correlate patent fees with patent value, the financial and strategic consequences would largely depend on the specifics of how, when and how often patent values are assessed, say attorneys at Cleary.
-
Agentic AI Puts A New Twist On Attorney Ethics Obligations
As lawyers increasingly use autonomous artificial intelligence agents, disciplinary authorities must decide whether attorney responsibility for an AI-caused legal ethics violation is personal or supervisory, and firms must enact strong policies regarding agentic AI use and supervision, says Grace Wynn at HWG.
-
Using Reissue Applications To Strategically Improve Patents
Though reissue applications are an often-overlooked consideration in today's patent environment, they can offer powerful tools for correcting errors, strengthening patent protection, or adapting to evolving business and legal landscapes, says Curtis Powell at Wolf Greenfield.
-
FDA Transparency Plans Raise Investor Disclosure Red Flags
The U.S. Food and Drug Administration’s recently announced intent to publish complete response letters for unapproved drugs and devices implicates certain investor disclosure requirements under securities laws, making it necessary for life sciences and biotech companies to adopt robust controls going forward, say attorneys at Arnold & Porter.
-
Series
Being A Professional Wrestler Makes Me A Better Lawyer
Pursuing my childhood dream of being a professional wrestler has taught me important legal career lessons about communication, adaptability, oral advocacy and professionalism, says Christopher Freiberg at Midwest Disability.
-
Patent Claim Lessons From Fed. Circ.'s Teva Decision
The Federal Circuit's recent decision in Janssen v. Teva is an important precedent for parties drafting patent claims or litigating obviousness where the prior art has potentially overlapping ranges for a claimed element, and may be particularly instructive to patent applicants in the pharmaceutical field, say attorneys at Cooley.